High-Risk APL: Targeted Therapy Outshines Chemo

In phase 3 APOLLO trial, ATRA-ATO combination therapy showed superior outcomes for high-risk acute promyelocytic leukemia.
Medscape Medical News

source https://www.medscape.com/viewarticle/high-risk-apl-targeted-therapy-outshines-chemo-2025a1000m77?src=rss